查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1810972

2025年神經基因體學全球市場報告

Neurogenomics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年神經基因組學市場將快速成長，到 2029 年將達到 26 億美元，複合年成長率為 14.7%。預測期內的成長可歸因於人們對心理健康個性化治療的興趣日益濃厚、直接面對消費者的神經遺傳學檢測的使用日益增多、多體學方法的採用日益增多、精準神經病學舉措的不斷擴展以及標靶治療的使用日益增多。在此期間，預計的主要趨勢包括人工智慧基因組分析的發展、非侵入性診斷平台的演變、多體學技術的整合、基因組學與精準神經病學的結合以及神經退化性疾病建模的創新。

神經系統疾病盛行率的上升預計將在未來幾年推動神經基因組學市場的成長。神經系統疾病是一種影響大腦、脊髓和神經的疾病，會導致肌肉無力、癲癇、慢性疼痛和認知障礙等症狀。盛行率的上升主要是由於生活方式相關因素，例如不良飲食、缺乏運動、慢性壓力以及環境毒素暴露增加。神經基因組學在治療這些疾病方面發揮關鍵作用，它能深入了解大腦功能和功能障礙的遺傳基礎，從而改善診斷、找出根本原因並實現有針對性的治療。例如，2023 年 3 月，阿茲海默症症協會報告稱，約有 670 萬 65 歲及以上的美國人患有老年失智症失智症。預計到 2060 年，這一數字將增加到 1,380 萬。因此，神經系統疾病盛行率的上升正在促進神經基因組學市場的擴張。

神經基因組學市場的主要企業專注於最尖端科技，例如全基因組定序平台，以改善對罕見和複雜神經系統疾病的診斷和理解。全基因定序平台分析個別基因組的完整 DNA 序列，有助於識別與神經系統疾病相關的遺傳因子。例如，2023 年 4 月，專門研究罕見疾病的德國診斷和研究公司 Centogene NV 推出了 CentoGenome，這是全球最全面的診斷罕見和神經退化性疾病的全基因組定序 (WGS) 解決方案。該平台採用非 PCR 技術進行高品質、無偏差定序，尤其是在難以定序的基因區域。先進的生物資訊流程和專家分析可改善變異檢測，在一次測試中捕捉幾乎所有致病變異。該服務還包括終身綜合診斷支持，如果發現新的遺傳發現，則提供免費的變異重新分類和確認測試。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球神經基因組學：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球神經基因體學市場：成長率分析
  • 全球神經基因組學市場表現：規模與成長，2019-2024
  • 全球神經基因組學市場預測：規模與成長，2024-2029 年，2034 年
  • 全球神經基因體學：總潛在市場（TAM）

第6章市場區隔

  • 全球神經基因體學市場：依產品、實際狀況及預測，2019-2024 年、2024-2029 年、2034 年
  • 次世代定序
  • 聚合酵素鏈鎖反應
  • 微陣列
  • 軟體和服務
  • 全球神經基因體學市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 突變體的發現
  • 調查應用
  • 目標識別
  • 轉錄因子結合分析
  • 功能研究
  • 臨床應用
  • 全球神經基因組學市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 製藥和生物技術公司
  • 學術研究機構
  • 醫院和診斷實驗室
  • 全球神經基因體學市場：依次世代定序（按類型）、實際與預測，2019-2024 年、2024-2029 年、2034 年
  • 全基因組序列分析
  • 全EXOME定序
  • 標靶定序
  • 核糖核酸序列分析
  • 全球神經基因體學市場：聚合酵素鏈鎖反應（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 即時聚合酵素鏈鎖反應
  • 逆轉錄聚合酵素鏈鎖反應
  • 數位聚合酵素鏈鎖反應
  • 全球神經基因組學市場：按微陣列類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 去氧核糖核酸微陣列
  • 核糖核酸微陣列
  • 蛋白質微陣列
  • 全球神經基因組學市場：按軟體和服務細分（按類型）、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 數據分析與解釋軟體
  • 基因組資料管理工具
  • 客製化服務
  • 雲端基礎的平台和報告工具

第7章 區域和國家分析

  • 全球神經基因體學市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球神經基因體學市場：依國家/地區、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 神經基因體學市場：競爭格局
  • 神經基因組學市場：公司簡介
    • F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Agilent Technologies Inc.
  • Illumina Inc.
  • Revvity Inc.
  • QIAGEN NV
  • Myriad Genetics Inc.
  • GeneDx LLC
  • Fulgent Genetics Inc.
  • Oxford Nanopore Technologies Plc
  • Vigil Neuroscience Inc.
  • PacBio
  • MedGenome Labs Ltd.
  • MGI Tech Co. Ltd.
  • Centogene NV
  • Variantyx Inc.
  • Neurogene

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年神經基因體學市場：提供新機會的國家
  • 2029年神經基因體學市場：細分領域帶來新機會
  • 2029年神經基因體學市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第36章 附錄

簡介目錄
Product Code: r37074

Neurogenomics is the study of how the genome affects the development and function of the nervous system, integrating neuroscience and genomics to better understand brain-related diseases, behavior, and cognition. Through the analysis of gene expression and genetic variations, researchers aim to uncover the underlying mechanisms of neurological disorders, advancing personalized medicine approaches in neurology.

The primary offerings in neurogenomics include next-generation sequencing (NGS), polymerase chain reaction (PCR), microarrays, and related software and services. Next-generation sequencing is a high-throughput DNA sequencing technology that enables the rapid and parallel analysis of millions of DNA fragments to determine their precise sequence. These technologies support a wide array of applications, including variant discovery, research studies, target identification, transcription factor binding analysis, functional genomics, and clinical diagnostics. Key end users include pharmaceutical and biotechnology companies, academic and research institutions, and hospitals and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The neurogenomics market research report is one of a series of new reports from The Business Research Company that provides neurogenomics market statistics, including neurogenomics global market size, regional shares, competitors with neurogenomics market share, detailed neurogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the neurogenomics industry. The neurogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurogenomics market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 15.0%. Growth during the historic period can be attributed to the rising demand for genetic testing in neurological disorders, increased research on the connections between the brain, behavior, and genome, the growing prevalence of neurodegenerative diseases, increased funding for neuroscience research, and the expansion of biobanks and genomic databases.

The neurogenomics market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. Growth in the forecast period can be attributed to the rising interest in personalized treatments for mental health, increased use of direct-to-consumer neurogenetic testing, growing adoption of multi-omics approaches, expansion of precision neurology initiatives, and greater use of targeted therapies. Key trends expected during this period include the development of artificial intelligence-powered genomic analytics, advancements in non-invasive diagnostic platforms, integration of multi-omics technologies, incorporation of genomics into precision neurology, and innovations in modeling neurodegenerative diseases.

The rising prevalence of neurological disorders is expected to drive the growth of the neurogenomics market in the coming years. Neurological disorders are medical conditions that impact the brain, spinal cord, or nerves and can cause symptoms such as muscle weakness, seizures, chronic pain, or cognitive impairments. This increase in prevalence is largely attributed to lifestyle-related factors, including poor dietary habits, insufficient physical activity, chronic stress, and greater exposure to environmental toxins. Neurogenomics plays a crucial role in addressing these disorders by offering insights into the genetic underpinnings of brain function and dysfunction, thereby improving diagnosis, identifying root causes, and enabling targeted treatments. For example, in March 2023, the Alzheimer's Association reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia. This figure is projected to increase to 13.8 million by 2060. Thus, the growing incidence of neurological disorders is contributing to the expansion of the neurogenomics market.

Leading companies in the neurogenomics market are focusing on developing cutting-edge technologies such as whole genome sequencing platforms to improve the diagnosis and understanding of rare and complex neurological conditions. Whole genome sequencing platforms analyze the complete DNA sequence of an individual's genome and are instrumental in identifying genetic factors linked to neurological disorders. For instance, in April 2023, Centogene N.V., a Germany-based diagnostics and research company specializing in rare diseases, introduced CentoGenome, the world's most comprehensive whole-genome sequencing (WGS) solution for diagnosing rare and neurodegenerative conditions. This platform incorporates PCR-free technology for high-quality, unbiased sequencing, particularly across difficult-to-sequence genetic regions. It improves variant detection through a sophisticated bioinformatics pipeline and expert analysis, capturing nearly all disease-causing variants in a single test. The service also includes integrated, lifelong diagnostic support, with free variant reclassification and confirmatory testing as new genetic insights emerge.

In February 2025, Tempus AI Inc., a US-based health technology company, acquired Ambry Genetics for $600 million. This acquisition was intended to enhance Tempus AI's precision medicine platform by incorporating Ambry Genetics' specialized capabilities in hereditary and clinical genetic testing. The integration broadens Tempus AI's reach across various therapeutic areas, including oncology, cardiology, rare diseases, and neurological conditions. Ambry Genetics Corporation, a US-based genetic testing company, provides neurogenomics services through a wide array of genetic testing options for neurological and neurodevelopmental disorders.

Major players in the neurogenomics market are F. Hoffmann-La Roche Limited, Thermo Fisher Scientific Incorporated, Danaher Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., Myriad Genetics Inc., GeneDx LLC, Fulgent Genetics Inc., Oxford Nanopore Technologies Plc., Vigil Neuroscience Inc., PacBio, MedGenome Labs Ltd., MGI Tech Co. Ltd., Centogene N.V., Variantyx Inc., and Neurogene.

North America was the largest region in the neurogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurogenomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenomics market consists of revenues earned by entities by providing services such as genomic sequencing services, bioinformatics and data analysis, research and clinical trial support, customized gene panel development, and pharmacogenomics services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurogenomics market also includes sales of genomic sequencing kits, microarray chips, bioinformatics software, neurogenomic biomarkers, and single-cell genomics kits. Values in this market are 'factory gate' values that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenomics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenomics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Offering: Next-Generation Sequencing; Polymerase Chain Reaction; Microarray; Software And Services
  • 2) By Application: Variant Discovery; Research Applications; Target Identification; Transcription Factor Binding Analysis; Functional Studies; Clinical Applications
  • 3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Hospitals And Diagnostic Laboratories
  • Subsegments:
  • 1) By Next-Generation Sequencing: Whole Genome Sequencing; Whole Exome Sequencing; Targeted Sequencing; Ribonucleic Acid Sequencing
  • 2) By Polymerase Chain Reaction: Real-Time Polymerase Chain Reaction; Reverse Transcription Polymerase Chain Reaction; Digital Polymerase Chain Reaction
  • 3) By Microarray: Deoxyribonucleic Acid Microarray; Ribonucleic Acid Microarray; Protein Microarray
  • 4) By Software And Services: Data Analysis And Interpretation Software; Genomic Data Management Tools; Custom Services; Cloud-Based Platforms And Reporting Tools
  • Companies Mentioned: F. Hoffmann-La Roche Limited; Thermo Fisher Scientific Incorporated; Danaher Corporation; Quest Diagnostics Incorporated; Eurofins Scientific SE; Agilent Technologies Inc.; Illumina Inc.; Revvity Inc.; QIAGEN N.V.; Myriad Genetics Inc.; GeneDx LLC; Fulgent Genetics Inc.; Oxford Nanopore Technologies Plc; Vigil Neuroscience Inc.; PacBio; MedGenome Labs Ltd.; MGI Tech Co. Ltd.; Centogene N.V.; Variantyx Inc.; Neurogene.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurogenomics Market Characteristics

3. Neurogenomics Market Trends And Strategies

4. Neurogenomics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurogenomics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurogenomics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurogenomics Market Growth Rate Analysis
  • 5.4. Global Neurogenomics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurogenomics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurogenomics Total Addressable Market (TAM)

6. Neurogenomics Market Segmentation

  • 6.1. Global Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Microarray
  • Software And Services
  • 6.2. Global Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Variant Discovery
  • Research Applications
  • Target Identification
  • Transcription Factor Binding Analysis
  • Functional Studies
  • Clinical Applications
  • 6.3. Global Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmaceutical And Biotechnology Companies
  • Academic And Research Institutes
  • Hospitals And Diagnostic Laboratories
  • 6.4. Global Neurogenomics Market, Sub-Segmentation Of Next-Generation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Whole Genome Sequencing
  • Whole Exome Sequencing
  • Targeted Sequencing
  • Ribonucleic Acid Sequencing
  • 6.5. Global Neurogenomics Market, Sub-Segmentation Of Polymerase Chain Reaction, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Real-Time Polymerase Chain Reaction
  • Reverse Transcription Polymerase Chain Reaction
  • Digital Polymerase Chain Reaction
  • 6.6. Global Neurogenomics Market, Sub-Segmentation Of Microarray, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Deoxyribonucleic Acid Microarray
  • Ribonucleic Acid Microarray
  • Protein Microarray
  • 6.7. Global Neurogenomics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Analysis And Interpretation Software
  • Genomic Data Management Tools
  • Custom Services
  • Cloud-Based Platforms And Reporting Tools

7. Neurogenomics Market Regional And Country Analysis

  • 7.1. Global Neurogenomics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurogenomics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenomics Market

  • 8.1. Asia-Pacific Neurogenomics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenomics Market

  • 9.1. China Neurogenomics Market Overview
  • 9.2. China Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenomics Market

  • 10.1. India Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenomics Market

  • 11.1. Japan Neurogenomics Market Overview
  • 11.2. Japan Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenomics Market

  • 12.1. Australia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenomics Market

  • 13.1. Indonesia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenomics Market

  • 14.1. South Korea Neurogenomics Market Overview
  • 14.2. South Korea Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenomics Market

  • 15.1. Western Europe Neurogenomics Market Overview
  • 15.2. Western Europe Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenomics Market

  • 16.1. UK Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenomics Market

  • 17.1. Germany Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenomics Market

  • 18.1. France Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenomics Market

  • 19.1. Italy Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenomics Market

  • 20.1. Spain Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenomics Market

  • 21.1. Eastern Europe Neurogenomics Market Overview
  • 21.2. Eastern Europe Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenomics Market

  • 22.1. Russia Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenomics Market

  • 23.1. North America Neurogenomics Market Overview
  • 23.2. North America Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenomics Market

  • 24.1. USA Neurogenomics Market Overview
  • 24.2. USA Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenomics Market

  • 25.1. Canada Neurogenomics Market Overview
  • 25.2. Canada Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenomics Market

  • 26.1. South America Neurogenomics Market Overview
  • 26.2. South America Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenomics Market

  • 27.1. Brazil Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenomics Market

  • 28.1. Middle East Neurogenomics Market Overview
  • 28.2. Middle East Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenomics Market

  • 29.1. Africa Neurogenomics Market Overview
  • 29.2. Africa Neurogenomics Market, Segmentation By Offering, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurogenomics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurogenomics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenomics Market Competitive Landscape And Company Profiles

  • 30.1. Neurogenomics Market Competitive Landscape
  • 30.2. Neurogenomics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eurofins Scientific SE Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenomics Market Other Major And Innovative Companies

  • 31.1. Agilent Technologies Inc.
  • 31.2. Illumina Inc.
  • 31.3. Revvity Inc.
  • 31.4. QIAGEN N.V.
  • 31.5. Myriad Genetics Inc.
  • 31.6. GeneDx LLC
  • 31.7. Fulgent Genetics Inc.
  • 31.8. Oxford Nanopore Technologies Plc
  • 31.9. Vigil Neuroscience Inc.
  • 31.10. PacBio
  • 31.11. MedGenome Labs Ltd.
  • 31.12. MGI Tech Co. Ltd.
  • 31.13. Centogene N.V.
  • 31.14. Variantyx Inc.
  • 31.15. Neurogene

32. Global Neurogenomics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenomics Market

34. Recent Developments In The Neurogenomics Market

35. Neurogenomics Market High Potential Countries, Segments and Strategies

  • 35.1 Neurogenomics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurogenomics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurogenomics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer